Loading stock data…
$3.81-0.02 (-0.52%)
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Recursion Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.81 with a market capitalization of $2.1B. Wall Street consensus targets $7.22 (6 analysts), implying a +89.2% move over the next 12 months. The stock is currently 47% below its 52-week high of $7.18, remaining 6.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.30M↑ | $6.30M↓ | $35.35M↑ | $4.98M↓ | $19.10M |
| Gross Profit | -$4.19M↑ | -$6.19M↓ | $21.08M↑ | -$9.70M↓ | -$1.06M |
| Operating Income | -$134.97M↓ | -$128.50M↓ | -$108.33M↑ | -$172.20M↑ | -$176.23M |
| Net Income | -$131.00M↓ | -$117.50M↓ | -$108.12M↑ | -$162.25M↑ | -$171.90M |
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug...